Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Presented by The Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care   The Big Story Kennedy on ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. Let's consider four ...

Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss.

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

WeightWatchers has filed for bankruptcy in the US as it struggles with debt and fierce competition from fat-loss jabs like ...

With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

U.S. energy firms seek exemption from Trump to transport LNG on U.S.-built ships. China Airlines orders Boeing passenger and ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...